422.jpg)
Glenmark Pharmaceuticals said on Friday that the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients. "Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection," Glenmark said in a statement.
Glenmark Pharmaceuticals said on Friday that the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients. "Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection," Glenmark said in a statement.
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
5.jpeg)
4.jpeg)
6.jpeg)
5.jpeg)
